Scarica l'app Stockscreener
86.60
1.70%
-1.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$88.10
Aprire:
$88.21
Volume 24 ore:
4.00M
Relative Volume:
0.99
Capitalizzazione di mercato:
$49.92B
Reddito:
$6.30B
Utile/perdita netta:
$1.07B
Rapporto P/E:
47.05
EPS:
1.8406
Flusso di cassa netto:
$1.09B
1 W Prestazione:
+1.63%
1M Prestazione:
-3.00%
6M Prestazione:
+9.55%
1 anno Prestazione:
+19.20%
Intervallo 1D:
$86.08
$88.40
Intervallo di 1 settimana:
$84.55
$88.41
Portata 52W:
$72.42
$96.29
Edwards Lifesciences Corp Stock (EW) Company Profile
Nome
Edwards Lifesciences Corp
Settore
Industria
Telefono
(949) 250-2500
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, MDT, SYK, BSX
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-07 | Iniziato | Barclays | Overweight |
| 2026-07-28 | Iniziato | UBS | Buy |
| 2026-07-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2026-04-01 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-12-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-10-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-04-24 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Aggiornamento | Stifel | Hold → Buy |
| 2025-01-16 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-31 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | Truist | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-02-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-28 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-03-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Downgrade | Bernstein | Outperform → Underperform |
| 2023-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Downgrade | Stifel | Buy → Hold |
| 2022-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Iniziato | Mizuho | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-29 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Iniziato | Truist | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-03-16 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-27 | Reiterato | Citigroup | Buy |
| 2022-01-27 | Reiterato | Evercore ISI | Outperform |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | Stifel | Buy |
| 2022-01-27 | Reiterato | UBS | Neutral |
| 2021-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-30 | Reiterato | Deutsche Bank | Hold |
| 2021-07-30 | Reiterato | Jefferies | Buy |
| 2021-07-30 | Reiterato | Morgan Stanley | Overweight |
| 2021-07-30 | Reiterato | Oppenheimer | Outperform |
| 2021-07-30 | Reiterato | Stifel | Buy |
| 2021-07-30 | Reiterato | UBS | Neutral |
| 2021-07-30 | Reiterato | Wells Fargo | Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-04-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-11 | Reiterato | Canaccord Genuity | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Underperform |
| 2020-04-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Outperform |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-09-23 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-24 | Reiterato | BofA/Merrill | Buy |
| 2019-03-18 | Reiterato | Canaccord Genuity | Buy |
| 2019-01-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Hold |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-10-02 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Downgrade | Guggenheim | Buy → Neutral |
Mostra tutto
Edwards Lifesciences Corp Borsa (EW) Ultime notizie
FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death - Benzinga
Edwards Lifesciences Corporation $EW Stock: Assenagon Asset Management S.A. Boosts Stake - MarketBeat
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences Corporation $EW Stock Sold by Ninety One UK Ltd - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Ninety One North America Inc. - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences Earnings Preview: What to Expect - Yahoo Finance
Edwards Lifesciences Earnings Preview: What to Expect - Barchart.com
Edwards Lifesciences Earnings Preview: What to Expect - inkl
Edwards Lifesciences Corporation (EW) Options ChainYahoo Finance - Yahoo! Finance Canada
Edwards Lifesciences Corporation (EW) Options Chain - Yahoo! Finance Canada
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences CVP Daniel Lippis sells $53k in stock - Investing.com
Edwards Lifesciences Corp (EW) Insider Daniel Lippis Sells 619 S - GuruFocus
Edwards Lifesciences (NYSE:EW) VP Daniel Lippis Sells 619 Shares of Stock - MarketBeat
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Is Edwards Lifesciences (NYSE:EW) Entering A Stronger Phase? - Kalkine Media
Why Edwards Lifesciences (EW) Stock Is Falling Today - Quiver Quantitative
UBS reiterates Edwards Lifesciences stock rating on endpoint expectations - Investing.com
Edwards Lifesciences (EW) Stock Forecast and Price Target 2026 $EW - MarketBeat
Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise? - Zacks Investment Research
Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026 - BioSpace
Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026 - Yahoo Finance
Edwards Lifesciences Corp (CEUX:EWLd) Stock Earnings Transcripts - GuruFocus
Edwards Lifesciences (NYSE:EW) Share Price Breaks Above Two Hundred Day Moving AverageWhat's Next? - marketbeat.com
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
What Does Expanded TAVR Coverage Mean for Edwards Lifesciences (NYSE:EW)? - Kalkine Media
Evercore ISI Adjusts Price Target on Edwards Lifesciences to $102 From $100, Keeps Outperform Rating - Yahoo Finance
Edwards Lifesciences to Host Investor Event in Conjunction With TCT - Yahoo Finance
Edwards Lifesciences Secures FDA Approval for First Expandable Pediatric Heart Valve - Benzinga
JPMorgan Adjusts Price Target on Edwards Lifesciences to $105 From $100, Keeps Overweight Rating - marketscreener.com
Edwards Lifesciences (NYSE:EW) Stock Forecast & Analyst Predictions - Simply Wall Street
Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients - BioSpace
Edwards Lifesciences wins FDA approval for AUTUS - Mugglehead Investment Magazine
Edwards Lifesciences (EW) Gains FDA Clearance for AUTUS Size-Adj - GuruFocus
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Edwards Lifesciences Receives FDA Approval For AUTUS Size-Adjustable Valve - marketscreener.com
For Edwards Lifesciences, Singapore is integral to its global supply chain strategy - Singapore Economic Development Board (EDB)
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
ETFs Investing in Edwards Lifesciences Corporation Stocks - tradingview.com
Edwards Lifesciences Corporation (NYSE:EW) Stock Has Average Target Price of $100.27 - MarketBeat
Claim your share of the $39 million Edwards Lifesciences securities class action settlement - Claim Depot
EW News | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
EW IMPORTANT DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Edwards Lifesciences Corporation Investors to Secure Counsel Before Important December 13 Deadline in Securities Class ActionEW - TMX Newsfile
Andra AP fonden Boosts Stake in Edwards Lifesciences Corporation $EW - MarketBeat
For Edwards Lifesciences, Singapore is integral to its global supply chain strategy - Singapore Economic Development Board (EDB)
How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions - Yahoo Finance
Edwards Lifesciences Corp Azioni (EW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Edwards Lifesciences Corp Azioni (EW) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lippis Daniel J. | CVP, TAVR |
Oct 08 '26 |
Sale |
85.65 |
619 |
53,017 |
40,034 |
| Lippis Daniel J. | CVP, TAVR |
Sep 11 '26 |
Option Exercise |
72.68 |
619 |
44,989 |
40,653 |
| Lippis Daniel J. | CVP, TAVR |
Sep 11 '26 |
Sale |
87.51 |
619 |
54,169 |
40,034 |
| Dahl Andrew M. | SVP, Corporate Controller |
Aug 31 '26 |
Sale |
91.06 |
544 |
49,534 |
14,868 |
| Dahl Andrew M. | Officer |
Aug 31 '26 |
Proposed Sale |
91.06 |
544 |
49,534 |
0 |
| Bruls Annette | CVP, EMEACLA |
Aug 28 '26 |
Sale |
89.98 |
2,644 |
237,907 |
17,984 |
| Bruls Annette | Officer |
Aug 28 '26 |
Proposed Sale |
89.98 |
2,644 |
237,907 |
0 |
| Markowitz Wayne | CVP, JAPAC |
Aug 26 '26 |
Sale |
91.47 |
1,240 |
113,417 |
20,294 |
| Markowitz Wayne | Officer |
Aug 26 '26 |
Proposed Sale |
91.47 |
1,240 |
113,417 |
0 |
| Chopra Daveen | Officer |
Aug 26 '26 |
Proposed Sale |
91.02 |
31,800 |
2,894,440 |
0 |
0.57%
1.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):